Objectif The complex physiopathology of human chronic diseases includes networks robustness, feedback loops, and cross-talks, which may induce limited efficacy, resistance, and/or excessive toxicity of an individual drug. Learning how to combine drugs in order to improve treatment efficacy and lower undesired toxicity is a major biomedical challenge. Current strategies for drug repositioning and optimization of drug combinations have two man limitations: 1) they mostly use public data and databases, which are based on knowledge of individual drug stimuli and do not specifically analyze interactions, 2) they consider limited number of cellular outputs to analyze the response to a drug. In DrugSynergy, we will use an innovative systems biology large-scale data-driven approach to determine the interaction between two drugs at the highest possible resolution. Our computational analysis workflow has been extensively validated over the past years. It is now robust enough to be applied for the optimization of drug combinations.Our business development strategies will follow several possible non-exclusive scenarios: 1) service providing to pharmaceutical and biotech companies to optimize their own pipeline of drug combinations, 2) generate intellectual property (IP) through identification of new drug combinations, optimization of existing drug combinations by addition of innovative drugs through screening of small molecule libraries, including from our Institute. These goals will be achieved in an academic structure, through licensing new IP to industrial partners, or within a start-up company created around the innovative pipelines and know-how of DrugSynergy. These options will be explored with our business development and industrial partnership department.DrugSynergy is expected to have a strong biomedical and socio-economic impact because of the growing need of efficiently combine multiple drugs to address health challenges such as cancer and chronic inflammatory diseases. Champ scientifique natural sciencescomputer and information sciencesdatabasesmedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicineoncology Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-PoC-2015 - ERC Proof of Concept Grant Appel à propositions ERC-2015-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil INSTITUT CURIE Contribution nette de l'UE € 150 000,00 Adresse RUE D ULM 26 75231 Paris France Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 150 000,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire INSTITUT CURIE France Contribution nette de l'UE € 150 000,00 Adresse RUE D ULM 26 75231 Paris Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 150 000,00
